Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RZLT |
---|---|---|
09:35 ET | 200 | 0.819 |
09:37 ET | 800 | 0.8199 |
09:48 ET | 932 | 0.82 |
10:18 ET | 31896 | 0.7705 |
10:20 ET | 200 | 0.7707 |
11:16 ET | 400 | 0.78 |
12:21 ET | 1000 | 0.78 |
12:28 ET | 700 | 0.7601 |
12:33 ET | 100 | 0.78 |
01:06 ET | 300 | 0.7799 |
01:49 ET | 2500 | 0.78 |
02:20 ET | 635 | 0.7799 |
02:30 ET | 2925 | 0.77 |
02:48 ET | 2868 | 0.78 |
03:01 ET | 100 | 0.7878 |
03:06 ET | 4831 | 0.7741 |
03:51 ET | 100 | 0.7878 |
04:00 ET | 1654 | 0.8066 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Rezolute Inc | 32.0M | -0.7x | --- |
Cardio Diagnostics Holdings Inc | 31.8M | -1.7x | --- |
NRX Pharmaceuticals Inc | 31.3M | -0.7x | --- |
Neoleukin Therapeutics Inc | 32.9M | -0.3x | --- |
Biora Therapeutics Inc | 32.0M | -0.1x | --- |
Nascent Biotech Inc | 33.3M | -9.8x | --- |
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-1.10 |
Book Value | $3.15 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.